Trial Profile
Retrospective Safety Survey In Patients Included In Phase I-II NV1FGF Clinical Trials
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 04 Jun 2014
Price :
$35
*
At a glance
- Drugs Riferminogene pecaplasmide (Primary)
- Indications Peripheral arterial disorders; Peripheral arterial occlusive disorders
- Focus Adverse reactions
- Acronyms TALISMAN S
- Sponsors Sanofi
- 04 Jun 2014 New trial record